Oh Young Bang/LinkedIn
Oct 6, 2025, 03:41
Oh Young Bang: We Are Carefully Preparing to Begin the First Cinical Trial of Exosome Therapy for Stroke in Korea
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We are carefully preparing to begin the first clinical trial of exosome therapy for stroke in Korea, prioritizing safety over speed.”
Read more on the announcement here.
S and E Bio, a biotechnology company focused on exosomal microRNA-based therapies, has obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) to begin a Phase 1b clinical trial of its investigational stroke treatment, SNE-101.
This marks the first exosome-based therapy in Korea to advance to clinical trials, representing a significant milestone in the nation’s biopharmaceutical industry.
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications